Rare diseases, MNCs grow presence on China’s NRDL

Though the details of price concessions won’t be made public for weeks, a look at China’s new National Reimbursement Drug List finds rare diseases and multinational companies growing their presence.

The NRDL has been gaining increasing international attention since 2018, when China established its National Healthcare Security Administration (NHSA) and started rolling out a series of policy reforms, including an annual update to the reimbursement list. ...